Chemistry:Deuremidevir
Deuremidevir, also known as VV116, is a nucleoside analogue antiviral drug. It is administrated through oral tablets, which contain the hydrobromide salt of this drug.[1]
The drug is a deuterated tri-isobutyrate of GS-441524, the active metabolite of remdesivir. It was first described in a November 2020 preprint by a team including members of Wuhan Institute of Virology and Vigonvita.[2] It completed a phase 3 trial in 2022.[3] Results from a separate Phase 3 trial conducted in mainland China from October 2022 to January 2023 suggested that deuremidevir may shorten the duration of COVID-19 symptoms in non-hospitalized adults with mild-to-moderate disease compared to placebo.[4] Junshi, which markets the drug, received conditional approval from China's National Medical Products Administration in January 2023.[5][6]
In November 2023, in response to viral mutations and changing characteristics of infection, the WHO adjusted its treatment guidelines. Among other changes, the use of deuremidevir was recommended against, except for clinical trials.[7]
Research
In preclinical studies, a single high dose of the drug (at least 1.0 g/kg) was shown to be tolerated in rats and dogs.[8]
References
- ↑ "Deuremidevir and Simnotrelvir-Ritonavir for the Treatment of COVID-19". ACS Pharmacology & Translational Science 6 (9): 1306–1309. September 2023. doi:10.1021/acsptsci.3c00134. PMID 37705591.
- ↑ Yin W, Luan X, Li Z, Xie Y, Zhou Z, Liu J, Gao M, Wang X, Zhou F, Wang Q, Wang Q (November 2020). "Structural basis for repurpose and design of nucleoside drugs for treating COVID-19". bioRxiv 10.1101/2020.11.01.363812.
- ↑ "VV116 versus Nirmatrelvir-Ritonavir for Oral Treatment of Covid-19". The New England Journal of Medicine 388 (5): 406–417. February 2023. doi:10.1056/NEJMoa2208822. PMID 36577095.
- ↑ "Oral VV116 versus placebo in patients with mild-to-moderate COVID-19 in China: a multicentre, double-blind, phase 3, randomised controlled study". The Lancet Infectious Diseases 24 (2): 129–139. February 2024. doi:10.1016/S1473-3099(23)00577-7. PMID 38006892.
- ↑ "China's NMPA conditionally approves two oral drugs for Covid-19" (in en-US). 2023-01-30. https://www.pharmaceutical-technology.com/news/china-nmpa-oral-drugs-covid-19/.
- ↑ "Remdesivir Derivative VV116 Is a Potential Broad-Spectrum Inhibitor of Both Human and Animal Coronaviruses". Viruses 15 (12): 2295. November 2023. doi:10.3390/v15122295. PMID 38140536.
- ↑ "WHO updates its guidance on treatments for COVID-19". BMJ. 9 November 2023. https://www.bmj.com/company/newsroom/who-updates-its-guidance-on-treatments-for-covid-19/.
- ↑ "Design and development of an oral remdesivir derivative VV116 against SARS-CoV-2". Cell Research 31 (11): 1212–1214. November 2021. doi:10.1038/s41422-021-00570-1. PMID 34584244.
 |  |
